Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug…
Anti-TROP-2 ADC with a drug payload SN38 (a DNA polymerase inhibitor) (ESG-401) has received FDA authorization to begin clinical trials in the US.ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors, including…